Abstract

Objective This is a 6 year retrospective analysis of the therapeutic efficacy and safety of Combined Aliskiren (150 mg a day) and Losartan (100 mg a day) in non Diabetic Chronic Kidney Disease (CKD) patients. The objective of this Second (2nd) Phase study was to ascertain the proportion of patients who would remain in remission for the next 3 years and for those who had a relapse of proteinuria after stopping treatment in order to decide when would be an optimum time to stop therapy as well as to ascertain the effects of stopping therapy. Method This is a 2nd Phase follow up study three years after the initial First (1st) Phase study. Patients in the 2nd Phase study were those who continued to have proteinuria and were treated with Losartan 100 mg a day compared to those with no proteinuria on completion of 1st Phase of the 6 year study. The 2nd Phase study seeks to document the incidence of relapse of proteinuria among the patients who had achieved a remission of proteinuria following their initial 1st Phase therapy for proteinuria. Results Among the 154 patients, 67/154 (44%) continued to have proteinuria, while 87/154 (56%) had no proteinuria (remission). Of these 87 patients, 43/154 (28%) had remission with no relapse for the 3 years and the other 44/154 (29%) had relapses. Conclusion A 3 year therapy appears to be an adequate duration for Angiotensin Receptor Blocker (ARB) therapy for proteinuria and though about a third (29%) may relapse, in the majority of cases, proteinuria was less than 0.5 gm/day.

Authors and Affiliations